Tag:
Cordis
Latest Headlines
Latest Headlines
Cordis appeals $40M award to Boston Sci
Patent disputes involving big names can involve big settlements. And a decision in favor of Boston Scientific ($BSX) over Johnson & Johnson ($JNJ) unit Cordis is no exception.
FDA clears Cordis' Empira catheters
The FDA has cleared Cordis' EMPIRA and EMPIRA NC RX PTCA dilatation catheters for the treatment of coronary artery disease. The U.S. launch is expected early next year. "The EMPIRA Balloon Catheters
J&J to exit stents, cut 1,000 jobs
While Johnson & Johnson has been putting out quality-control fires at its McNeil consumer health unit, it's had a smoldering problem in another segment of its business: cardiac stents. The
Cordis to rein in stent development, cut jobs
Johnson & Johnson's Cordis unit will no longer pursue the development of the Nevo sirolimus-eluting coronary stent so it can focus on other cardiovascular therapies, the company announced this
Appeals court finds for Boston Sci in stent case
A federal appeals court has given Boston Scientific a victory in a patent-infringement dispute with Johnson & Johnson in a case involving drug-eluting stents. The U.S. Court of Appeals for the
Acacia unit, Cordis resolve litigation
Acacia Research Corporation's EVM Systems subsidiary has entered a settlement agreement with Cordis Corporation regarding patents for shape memory metal medical instruments. Acacia's subsidiaries
Cordis alerts doctors on Cypher design spec problems
Johnson & Johnson's Cordis unit has sent doctors an alert stating the Cypher stent may not meet design specifications for proper expansion within heart arteries. The alert follows a mid-February
FDA warning letter tops off J&J recall news
More manufacturing-related woes for Johnson & Johnson. On top of yesterday's insulin-cartridge recall, the company got an FDA warning letter on a stent-making plant in Puerto Rico. First, the
J&J's Cordis unit hit with warning letter on stents
Johnson & Johnson's woes just won't end. The company's Cordis unit has received a warning letter dated Feb. 16 for problems at a stent plant in Puerto Rico resulting from an inspection that took
J&J's Cordis lays off, merges sales staff
With demand for its Cypher heart stent diminishing, Johnson & Johnson medical device subsidiary Cordis will lay off some sales reps and merge its cardiovascular and endovascular units sales
